Clinical trials: Hepatocellular Carcinoma(HCC)
Liver Biopsy
Identification of Liver Tumours Using BIP - Biopsy System
This clinical device investigation is conducted by performing liver biopsies using the BIP - Biopsy Tool. The aim is to assess the feasibility of bioimpedance spectroscopy based biopsy tool guidance method and test how well BIP…
- Trial name
- NCT02620228
- Testing
- BIP Biopsy System
- Where
- Finland
- Volunteers
- 26 people
- Sponsor
- Injeq Ltd
Advanced Liver Cancer
A Phase Ib/II Trial to Evaluate the Safety and Efficacy of QL1706 in Patients With Advanced Hepatocellular Carcinoma
This is a phase Ib/II trial to evaluate the safety, pharmacokinetics and preliminary efficacy of QL1706 or QL1604 combined with bevacizumab in patients with advanced hepatocellular carcinoma.
- Trial name
- NCT05603039
- Testing
- QL1706, QL1604, Bevacizumab
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Hepatocellular Carcinoma
ZG005 Plus Bevacizumab vs Sintilimab Plus Bevacizumab as First-Line Therapy for Advanced Hepatocellular
The purpose of the study is to evaluate the efficacy of ZG005 combined with bevacizumab compared with sintilimab combined with bevacizumab in the first-line treatment of participants with advanced HCC
- Trial name
- NCT07813572
- Testing
- ZG005 for Injection, Bevacizumab ( Avastin), Sintilimab
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
HCC, Hepatitis B Virus Related Hepatocellular Carcinoma
A Study of SCG101 TCR-T Cell Therpay in the Treatment of Subjects With Hepatitis B Virus-Related
This is a Phase I clinical study aimed to assess the safety, tolerability, and efficacy of SCG101 monotherapy for patients with HBV-HCC.
- Conditions
- HCC, Hepatitis B Virus Related Hepatocellular Carcinoma, Hepatocellular Carcinoma
- Trial name
- NCT06617000
- Testing
- SCG101
- Where
- 7 sites in China
- Volunteers
- 38 people
- Sponsor
- SCG Cell Therapy Pte. Ltd.
Lung Cancer, Squamous Cell Carcinoma
An Exploratory, Open Label, Multi-Center, Non-Randomized Study of [F-18]VM4-037
Phase: Exploratory Study Objectives: To collect drug bio-distribution data, begin collection of baseline and tumor/background imaging data, acquire experience to improve study design and the conduct of future studies Design…
- Conditions
- Lung Cancer, Squamous Cell Carcinoma, Head and Neck Cancer, Hepatic Carcinoma
- Trial name
- VM4-037 (NCT00884520)
- Testing
- [F-18] VM4-037
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Siemens Molecular Imaging
Carcinoma, Hepatocellular
A Dose-escalation Study of Lipotecan® Plus Radiotherapy in Locally Advanced Hepatocellular Carcinoma
Radiotherapy (R/T) for locally advanced hepatocellular carcinoma (HCC) is often used in patient who is not suitable for transarterial chemoembolization (TACE) and other local therapy, especially in those with portal vein tumor…
- Trial name
- NCT01425996
- Testing
- Lipotecan® (TLC388)
- Where
- 2 sites in Taiwan
- Volunteers
- 3 people
- Sponsor
- Taiwan Liposome Company
Hepatocellular Carcinoma (HCC)
Chidamide + Regorafenib in Hepatocellular Carcinoma (HCC)
This open-label, phase Ib/II, multicenter study evaluated the safety, tolerability, efficacy, and PK of chidamide in combination with regorafenib in patients with HCC.
- Trial name
- NCT05770882
- Testing
- Chidamide, Regorafenib
- Where
- 5 sites in Taiwan
- Volunteers
- 7 people
- Sponsor
- Great Novel Therapeutics Biotech & Medicals Corporation
Advanced Hepatocellular Carcinoma (HCC)
Phase 2 Study of WGI-0301 for Advanced HCC
The purpose of this study is to determine the MTD of WGI-0301 in combination with Sorafenib for advanced Hepatocellular Carcinoma (HCC) and assess its safety and efficacy in adults with advanced unresectable HCC who have…
- Trial name
- NCT06309485
- Testing
- WGI-0301 at MTD/RP2D dose IV infusion, QW, WGI-0301 at MTD/RP2D -1 dose IV infusion, QW, Sorafenib 400 mg PO, BID continuously
- Where
- 9 sites in China, Hong Kong
- Volunteers
- 60 people
- Sponsor
- Zhejiang Haichang Biotech Co., Ltd.
Melanoma, Breast Carcinoma
A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors
This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD/RD and regimen of XmAb20717, to describe safety and tolerability, to assess PK and immunogenicity, and to preliminarily assess anti-tumor activity…
- Conditions
- Melanoma, Breast Carcinoma, Hepatocellular Carcinoma, Urothelial Carcinoma
- Trial name
- DUET-2 (NCT03517488)
- Testing
- XmAb20717
- Where
- 17 sites in United States
- Volunteers
- 150 people
- Sponsor
- Xencor, Inc.
Advanced Hepatocellular Carcinoma
A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular Carcinoma
This study will be conducted in 2 parts. The first part is a phase 1 single-agent dose escalation, and dose optimization, study of tegavivint in patients with advanced HCC after failure of at least one line of prior systemic…
- Trial name
- NCT05797805
- Testing
- Tegavivint, Lenvatinib, Cabozantinib
- Where
- 8 sites in United States, Canada
- Volunteers
- 178 people
- Sponsor
- Iterion Therapeutics
Carcinoma, Hepatocellular
Nexavar Post-marketing Surveillance for Hepatocellular Carcinoma in Japan
This study is a regulatory post-marketing surveillance in Japan, and it is a local prospective and observational study of patients who have received Nexavar for unresectable hepatocellular carcinoma (HCC).
- Trial name
- NCT01411436
- Testing
- Sorafenib (Nexavar, BAY43-9006)
- Where
- Japan
- Volunteers
- 1,637 people
- Sponsor
- Bayer
Advanced Gastrointestinal (GI) Malignancies, Hepatocellular Carcinoma
Ph 1-2 Study ADI-PEG 20 Plus FOLFOX in Subjects With Advanced GI Malignancies Focusing on Hepatocellular Carcinoma
Phase 1: Assessment of safety and tolerability of ADI-PEG 20 in combination with folinic acid (leucovorin), fluorouracil and oxaliplatin (FOLFOX) in advanced GI malignancies.
- Conditions
- Advanced Gastrointestinal (GI) Malignancies, Hepatocellular Carcinoma, Gastric Cancer, Colorectal Cancer
- Trial name
- NCT02102022
- Testing
- ADI-PEG 20 plus modified FOLFOX6
- Where
- 35 sites in United States, China and 4 more
- Volunteers
- 140 people
- Sponsor
- Polaris Group
Hepatocellular Carcinoma
Study of ThermoDox With Standardized Radiofrequency Ablation (RFA) for Treatment of Hepatocellular Carcinoma (HCC)
The purpose of this study is to determine whether ThermoDox, a thermally sensitive liposomal doxorubicin, is effective in the treatment of non-resectable hepatocellular carcinoma when used in conjunction with standardized…
- Trial name
- OPTIMA (NCT02112656)
- Testing
- ThermoDox, Dummy infusion
- Where
- 61 sites in United States, Canada and 12 more
- Volunteers
- 554 people
- Sponsor
- Imunon
Advanced Hepatocellular Carcinoma
Study of Efficacy and Safety INC280 in Patients With Advanced Hepatocellular Carcinoma
This study is establish whether INC280 is safe and has beneficial effects in patients with advanced hepatocellular carcinoma known to have dysregulation of c-MET pathway and whose disease progressed while on, or after, treatment…
- Trial name
- NCT01964235
- Testing
- INC280
- Where
- 15 sites in United States, Australia and 5 more
- Sponsor
- Novartis Pharmaceuticals
Neoplasms
Asian Phase I Study Of PF-03446962
This is an Asian Phase 1, multi center, open label, single arm study of PF 03446962 with dose escalation and designed to define the Maximum Tolerated Dose [MTD] and the Recommended Phase 2 Dose [RP2D].
- Trial name
- NCT01337050
- Testing
- PF-03446962
- Where
- 2 sites in Japan, South Korea
- Volunteers
- 36 people
- Sponsor
- Pfizer
Advanced Solid Tumor, Metastatic Solid Tumors
Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET
A phase 1/2, first-in-human, open-label study of the safety, tolerability, PK, and efficacy of the novel MET/CSF1R/SRC inhibitor TPX-0022 in adult subjects with advanced or metastatic NSCLC, Gastric Cancer, or solid tumors…
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumors, MET Gene Alterations
- Trial name
- SHIELD-1 (NCT03993873)
- Testing
- elzovantinib (TPX-0022)
- Where
- 24 sites in United States, France and 3 more
- Volunteers
- 95 people
- Sponsor
- Turning Point Therapeutics, Inc.
Hepatocellular Carcinoma Non-resectable, Metastatic Colorectal Cancer
Safety and Effectiveness of Eye90 Microspheres™ in the Treatment of Unresectable Hepatocellular Carcinoma (HCC) and Metastatic Colorectal Cancer (mCRC)
The purpose of this study is to evaluate the safety of treatment with Eye90 microspheres in patients with unresectable Hepatocellular Carcinoma (HCC) and metastatic Colorectal Cancer (mCRC).
- Conditions
- Hepatocellular Carcinoma Non-resectable, Metastatic Colorectal Cancer, Liver Cancer
- Trial name
- NCT04926376
- Testing
- Eye90 Microspheres
- Where
- New Zealand
- Volunteers
- 8 people
- Sponsor
- ABK Biomedical
Hepatocellular Carcinoma
An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer
The first part of the study is the Dose Escalation Phase designed to establish the safety of nivolumab at different dose levels for each of the three cohorts (uninfected hepatocellular carcinoma (HCC) subjects, hepatitis C virus…
- Trial name
- CheckMate040 (NCT01658878)
- Testing
- Nivolumab, Sorafenib, Ipilimumab
- Where
- 60 sites in United States, Canada and 11 more
- Volunteers
- 657 people
- Sponsor
- Bristol-Myers Squibb
Carcinoma, Hepatocellular
Safety and Efficacy of Doxorubicin Adsorbed to Magnetic Beads Vs. IV Doxorubicin in Treating Liver Cancer
MTC-DOX is Doxorubicin or DOX, a chemotherapy drug, that is adsorbed, or made to "stick", to magnetic beads (MTCs). MTCs are tiny, microscopic particles of iron and carbon.
- Trial name
- NCT00034333
- Testing
- MTC-DOX for Injection
- Where
- 29 sites in United States, Austria and 6 more
- Volunteers
- 240 people
- Sponsor
- FeRx
Solid Tumor, Hepatocellular Carcinoma
Intravenous T3011 Given as a Single Agent and in Combination With Other Therapy in Subjects With Advanced Solid Tumors
A Phase 1/2a Open-Label Dose Escalation and Dose Expansion Study of T3011 when Administered Intravenously as a Single Agent and in Combination with Other Therapy in Subjects with Advanced Solid Tumors
- Conditions
- Solid Tumor, Hepatocellular Carcinoma, Colorectal Cancer, NSCLC
- Trial name
- NCT04780217
- Testing
- T3011
- Where
- 6 sites in United States
- Volunteers
- 42 people
- Sponsor
- ImmVira Pharma Co. Ltd